欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2020, Vol. 25 ›› Issue (10): 1195-1200.doi: 10.12092/j.issn.1009-2501.2020.10.016

• 综述与讲座 • 上一篇    

基于风险的临床试验质量管理

王永芳,宋梅宁,李博洋
  

  1. 烟台正海生物科技股份有限公司,烟台 264006,山东
  • 收稿日期:2020-04-30 修回日期:2020-09-13 出版日期:2020-10-26 发布日期:2020-11-03
  • 作者简介:王永芳,女,本科,初级工程师,研究方向:临床试验。 Tel: 0535-6397063 E-mail: wangyfjune@163.com
  • 基金资助:
    国家重点研发计划 生殖健康及重大出生缺陷防控研究重点专项(2016YFC1000800)

Risk based quality management in clinical trials

WANG Yongfang, SONG Meining, LI Boyang   

  1. Yantai Zhenghai Bio-Tech Co., Ltd. Yantai 264006, Shandong, China
  • Received:2020-04-30 Revised:2020-09-13 Online:2020-10-26 Published:2020-11-03

摘要: 本文依据《药物临床试验质量管理规范》相关规定,结合国内外发布的关于质量风险管理、基于风险的质量管理、风险管理等相关规定,从申办者角度梳理总结临床试验基于风险的质量管理的全过程以及每一过程的相关规定与建议,为下一步具体开展基于风险的质量管理工作提供理论基础。

关键词: 临床试验, 风险, 质量管理

Abstract: Based on the relevant provisions of the Standard for Good Clinical Practice, combining with the published at home and abroad about the quality of the quality risk management, risk-based quality management, risk management, and other related regulations, this paper summarizes the whole process of clinical trial risk-based quality management as well as the relevant regulations and suggestions for each process from the perspective of the sponsor. The aim is to provide theoretical basis for the next step of conducting risk-based quality management.

Key words: clinical trial, risk, quality management

中图分类号: